marijuana stocks

Form 8-K for VAPORIN, INC.


27-Feb-2015

Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders.On February 20, 2015, at a Special Meeting of Shareholders, the shareholders of Vaporin, Inc. approved all of the proposals put to a vote. The final vote results were as follows:

1. Approval of the Agreement and Plan of Merger, dated as of december 17, 2014, between Vapor Corp. and Vaporin, Inc. pursuant to which Vaporin, Inc. will merge with and into Vapor Corp.

Votes For Votes Against Abstentions Broker Non-Votes 4,421,792 3,291 799 –

2. Approval, on a non-binding advisory basis, of the compensation of the named executive officers of Vaporin, Inc. based on or related to the merger.

Votes For Votes Against Abstentions Broker Non-Votes 4,365,700 40,800 19,382 –

3. Approval of a proposal to authorize the Board of Directors to adjourn or postpone the special meeting to a later date, if necessary or appropriate, to solicit additional proxies in favor of approval of the merger agreement or to vote on other matters properly before such special meeting.

Votes For Votes Against Abstentions Broker Non-Votes 4,419,001 5,409 1,472 –

The outstanding voting power entitled to vote consisted of 6,543,252 votes.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Cronos Group Inc. (CRON) to Hold 2022 Second Quarter Earnings Conference Call on August 9, 2022

Cronos Group Inc. to Hold 2022 Second Quarter Earnings Conference Call on…

GT Biopharma Inc. (GTBP) Announces the Addition of Dr. John N. Bonfiglio to its Board of Directors

GT Biopharma Announces the Addition of Dr. John N. Bonfiglio to its…

$SRNA Announces New Chief Operating Officer

Surna Appoints Bryon Jorgenson as Chief Operating Officer BOULDER, CO–(Marketwired – Jan…

$PMCB Starts the Path to Phase II Clinicals – Small Cap Street

SHAREHOLDER UPDATE: PharmaCyte Biotech Starts the Path to Phase II Clinicals –…